{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T18:46:49Z","timestamp":1763318809749},"reference-count":75,"publisher":"Media Sphere Publishing Group","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vestn. oftal'mol."],"published-print":{"date-parts":[[2018]]},"DOI":"10.17116\/oftalma2018134041100","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T14:25:06Z","timestamp":1535639106000},"page":"100","source":"Crossref","is-referenced-by-count":5,"title":["The role of fixed dose combinations in the treatment of primary open-angle glaucoma"],"prefix":"10.17116","volume":"134","author":[{"given":"S. Yu.","family":"Petrov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. S.","family":"Zinina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Volzhanin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/oftalma2018134041100-1","unstructured":"Nesterov AP, Alekseev VN, Alekseev IB, Amirov AN, Astakhov YuS, Balalin SV. Natsional'noe rukovodstvo po glaukome dlya praktikuyuschikh vrachei. 3 izdanie, isprav. i dop. M.: GEOTAR-Media; 2015. (In Russ.)"},{"key":"key-10.17116\/oftalma2018134041100-2","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma. 4th edition ed: Savona, Italy PubliComm; 2014."},{"key":"key-10.17116\/oftalma2018134041100-3","unstructured":"Erichev VP, Egorov EA. Vestnik oftal'mologii. 2014;130(6):98-105. (In Russ.)"},{"key":"key-10.17116\/oftalma2018134041100-4","doi-asserted-by":"crossref","unstructured":"Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Kass MA. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Archives of ophthalmology. 2002;120(6):714-720; discussion 829-730.","DOI":"10.1001\/archopht.120.6.714"},{"key":"key-10.17116\/oftalma2018134041100-5","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.8.1030"},{"key":"key-10.17116\/oftalma2018134041100-6","doi-asserted-by":"crossref","unstructured":"Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of ophthalmology. 2002;120(10):1268-1279.","DOI":"10.1001\/archopht.120.10.1268"},{"key":"key-10.17116\/oftalma2018134041100-7","doi-asserted-by":"crossref","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Archives of ophthalmology. 2002;120(6):701-713; discussion 829-730.","DOI":"10.1001\/archopht.120.6.701"},{"key":"key-10.17116\/oftalma2018134041100-8","doi-asserted-by":"crossref","unstructured":"Webers CA, Beckers HJ, Nuijts RM, Schouten JS. Pharmacological management of primary open-angle glaucoma: second-line options and beyond. Drugs & aging. 2008;25(9):729-759.","DOI":"10.2165\/00002512-200825090-00002"},{"key":"key-10.17116\/oftalma2018134041100-9","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e3181815421"},{"key":"key-10.17116\/oftalma2018134041100-10","doi-asserted-by":"crossref","unstructured":"Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs & aging. 2007;24(12):1007-1016.","DOI":"10.2165\/00002512-200724120-00004"},{"key":"key-10.17116\/oftalma2018134041100-11","doi-asserted-by":"crossref","unstructured":"Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. Journal of pharmaceutical sciences. 1974;63(3):333-338.","DOI":"10.1002\/jps.2600630304"},{"key":"key-10.17116\/oftalma2018134041100-12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2004.12.035"},{"key":"key-10.17116\/oftalma2018134041100-13","unstructured":"Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clinical ophthalmology. 2010;4:1-9."},{"key":"key-10.17116\/oftalma2018134041100-14","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.139329"},{"key":"key-10.17116\/oftalma2018134041100-15","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1050851"},{"key":"key-10.17116\/oftalma2018134041100-16","doi-asserted-by":"crossref","unstructured":"Bron AM, Garcher CP, Sirbat D, Allaire CM, Lablache-Combier MJ, Trinquand CJ. Comparison of two fixed beta-blocker-pilocarpine combinations. The Carteolol-Pilocarpine Study Group. European journal of ophthalmology. 1997;7(4):351-356.","DOI":"10.1177\/112067219700700408"},{"key":"key-10.17116\/oftalma2018134041100-17","doi-asserted-by":"crossref","unstructured":"Demailly P, Allaire C, Bron V, Trinquand C. Effectiveness and Tolerance of beta-Blocker\/Pilocarpine Combination Eye Drops in Primary Open-Angle Glaucoma and High Intraocular Pressure. Journal of glaucoma. 1995;4(4):235-241.","DOI":"10.1097\/00061198-199508000-00004"},{"key":"key-10.17116\/oftalma2018134041100-18","doi-asserted-by":"crossref","unstructured":"Puustjarvi TJ, Repo LP. Timolol-pilocarpine fixed-ratio combinations in the treatment of chronic open angle glaucoma. A controlled multicenter study of 48 weeks. Scandinavian Timpilo Study Group. Archives of ophthalmology. 1992;110(12):1725-1729.","DOI":"10.1001\/archopht.1992.01080240065032"},{"key":"key-10.17116\/oftalma2018134041100-19","unstructured":"Robin AL. Ocular hypotensive efficacy and safety of a combined formulation of betaxolol and pilocarpine. Transactions of the American Ophthalmological Society. 1996;94:89-101; discussion 101-103."},{"key":"key-10.17116\/oftalma2018134041100-20","doi-asserted-by":"crossref","unstructured":"Podos SM, Camras CB, Serle JB. Experimental compounds to lower intraocular pressure. Australian and New Zealand journal of ophthalmology. 1989;17(2):129-135.","DOI":"10.1111\/j.1442-9071.1989.tb00502.x"},{"key":"key-10.17116\/oftalma2018134041100-21","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.1.4.815"},{"key":"key-10.17116\/oftalma2018134041100-22","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.010"},{"key":"key-10.17116\/oftalma2018134041100-23","doi-asserted-by":"crossref","unstructured":"Mincione F, Scozzafava A, Supuran CT. The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Current pharmaceutical design. 2008;14(7):649-654.","DOI":"10.2174\/138161208783877866"},{"key":"key-10.17116\/oftalma2018134041100-24","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.898"},{"key":"key-10.17116\/oftalma2018134041100-25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2007.01145.x"},{"key":"key-10.17116\/oftalma2018134041100-26","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0b013e32831eef4f"},{"key":"key-10.17116\/oftalma2018134041100-27","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.155317"},{"key":"key-10.17116\/oftalma2018134041100-28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.06.027"},{"key":"key-10.17116\/oftalma2018134041100-29","doi-asserted-by":"crossref","unstructured":"Diestelhorst M, Larsson LI, European Latanoprost Fixed Combination Study G. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. The British journal of ophthalmology. 2004;88(2):199-203.","DOI":"10.1136\/bjo.2003.018234"},{"key":"key-10.17116\/oftalma2018134041100-30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.10.053"},{"key":"key-10.17116\/oftalma2018134041100-31","doi-asserted-by":"publisher","DOI":"10.1089\/10807680260362687"},{"key":"key-10.17116\/oftalma2018134041100-32","unstructured":"Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic surgery. 1995;26(3):233-236."},{"key":"key-10.17116\/oftalma2018134041100-33","doi-asserted-by":"crossref","unstructured":"Dunker S, Schmucker A, Maier H, Latanoprost\/Timolol Fixed Combination Study G. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Advances in therapy. 2007;24(2):376-386.","DOI":"10.1007\/BF02849907"},{"key":"key-10.17116\/oftalma2018134041100-34","unstructured":"Kazanova SYu, Strakhov VV. Analysis of glaucoma process progression rates depending on various treatment non-compliance scenarios. Natsional'nyi zhurnal glaukoma. 2016;15(2):74-83. (In Russ.)"},{"key":"key-10.17116\/oftalma2018134041100-35","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903260129"},{"key":"key-10.17116\/oftalma2018134041100-36","unstructured":"Primary Open-angle Glaucoma, Preferred Practice Pattern. Ophthalmology A.A.o., editor2005."},{"key":"key-10.17116\/oftalma2018134041100-37","doi-asserted-by":"crossref","unstructured":"Brandt JD, Cantor LB, Katz LJ, Batoosingh AL, Chou C, Bossowska I, Ganfort Investigators G, II. Bimatoprost\/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. Journal of glaucoma. 2008;17(3):211-216. https:\/\/doi.rg\/o10.1097\/IJG.0b013e3181507313","DOI":"10.1097\/IJG.0b013e3181507313"},{"key":"key-10.17116\/oftalma2018134041100-38","doi-asserted-by":"crossref","unstructured":"Hommer A, Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%\/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. European journal of ophthalmology. 2007;17(1):53-62.","DOI":"10.1177\/112067210701700108"},{"key":"key-10.17116\/oftalma2018134041100-39","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.9.1230"},{"key":"key-10.17116\/oftalma2018134041100-40","unstructured":"Mandi\u0107 Z, Novak-Laus K, Boji\u0107 L, et al. Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%\/timolol 0.5%) in 6 months follow up period. Acta Clin Croat. 2010;49(4):411-419."},{"key":"key-10.17116\/oftalma2018134041100-41","unstructured":"Erichev VP, Filippova OM, Lovpache DN, Vasilenkova LV. Dry eye syndrome and local hypotensive therapy. Glaukoma. 2002;2:40. (In Russ.)"},{"key":"key-10.17116\/oftalma2018134041100-42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2005.02.043"},{"key":"key-10.17116\/oftalma2018134041100-43","doi-asserted-by":"crossref","unstructured":"Goni FJ, Brimonidine\/Timolol Fixed Combination Study G. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. European journal of ophthalmology. 2005;15(5):581-590.","DOI":"10.1177\/112067210501500508"},{"key":"key-10.17116\/oftalma2018134041100-44","doi-asserted-by":"crossref","unstructured":"Hommer A, Thygesen J, Ferreras A, Wickstrom J, Friis MM, Buchholz P, Walt JG. A European perspective on costs and cost effectiveness of ophthalmic combinations in the treatment of open-angle glaucoma. European journal of ophthalmology. 2008;18(5):778-786.","DOI":"10.1177\/112067210801800519"},{"key":"key-10.17116\/oftalma2018134041100-45","doi-asserted-by":"crossref","unstructured":"Hutzelmann J, Owens S, Shedden A, Adamsons I, Vargas E. Comparison of the safety and efficacy of the fixed combination of dorzolamide\/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. The British journal of ophthalmology. 1998;82(11):1249-1253.","DOI":"10.1136\/bjo.82.11.1249"},{"key":"key-10.17116\/oftalma2018134041100-46","doi-asserted-by":"publisher","DOI":"10.1185\/03007990802312567"},{"key":"key-10.17116\/oftalma2018134041100-47","doi-asserted-by":"crossref","unstructured":"Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1936-1944.","DOI":"10.1016\/S0161-6420(98)91045-4"},{"key":"key-10.17116\/oftalma2018134041100-48","doi-asserted-by":"crossref","unstructured":"Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. American journal of ophthalmology. 1998;126(4):487-497.","DOI":"10.1016\/S0002-9394(98)00223-2"},{"key":"key-10.17116\/oftalma2018134041100-49","doi-asserted-by":"crossref","unstructured":"The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators. American journal of ophthalmology. 2000;130(4):429-440.","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"key-10.17116\/oftalma2018134041100-50","doi-asserted-by":"crossref","unstructured":"Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, Early Manifest Glaucoma Trial G. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Archives of ophthalmology. 2003;121(1):48-56.","DOI":"10.1001\/archopht.121.1.48"},{"key":"key-10.17116\/oftalma2018134041100-51","doi-asserted-by":"publisher","DOI":"10.18008\/1816-5095-2016-3-135-143"},{"key":"key-10.17116\/oftalma2018134041100-52","unstructured":"Kuroyedov AV. Clinical and economic approaches to the glaucoma patients treatment. Oftal'mol vedomosti. 2010;3(1):51-62. (In Russ.)"},{"key":"key-10.17116\/oftalma2018134041100-53","doi-asserted-by":"crossref","unstructured":"Kuroyedov AV, Abysheva LD, Avdeev RV, Alexandrov AS, Basinsky AS, Blyum EA, Brezhnev AYu, Gazizova IR, Galimova AB, Gaponko OV, Garkavenko VV, Getmanova AM, Gorodnichy VV, Gorshkova MS, Gusarevitch AA, Diordiychuk SV, Dorofeev DA, Zhavoronkov SA, Zavadsky PCh, Zakhidov AB, Zvereva OG, Karimov UR, Kulik AV, Lanin SN, Lovpache DzhN, Loskutov IA, Molchanova EV, Nefedov NA, Ogorodnikova VYu, Onufrichuk ON, Petrov SYu, Rozhko YuI, Sidenko TA, Tashtitova LB, Khudzhatova MS. Medico-economic multicenter study of local hypotensive therapy efficacy and cost for patients with primary open-angle glaucoma in CIS. Oftal'mologij Vostochnay Evropa. 2015;3(26):35-51. (In Russ.)","DOI":"10.51523\/2708-6011.2015-12-1-6"},{"key":"key-10.17116\/oftalma2018134041100-54","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.067355"},{"key":"key-10.17116\/oftalma2018134041100-55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2005.00560.x"},{"key":"key-10.17116\/oftalma2018134041100-56","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.124.1.12"},{"key":"key-10.17116\/oftalma2018134041100-57","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.6.849"},{"key":"key-10.17116\/oftalma2018134041100-58","unstructured":"Str\u00f6m O. Medical costs of glaucoma in Sweden. International Society For Pharmacoeconomics and Outcomes Research (ISPOR). Toronto, Ontario, Canada, 3-7 May 2008."},{"key":"key-10.17116\/oftalma2018134041100-59","doi-asserted-by":"crossref","unstructured":"Nordmann JP, Lafuma A, Deschaseaux C, Berdeaux G. Clinical outcomes of glaucoma treatments over a patient lifetime: a Markov model. Journal of glaucoma. 2005;14(6):463-469.","DOI":"10.1097\/01.ijg.0000184834.93535.0b"},{"key":"key-10.17116\/oftalma2018134041100-60","doi-asserted-by":"crossref","unstructured":"van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, Schouten JS. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol. 2012;90(1):20-31.","DOI":"10.1111\/j.1755-3768.2011.02318.x"},{"key":"key-10.17116\/oftalma2018134041100-61","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2005.00616.x"},{"key":"key-10.17116\/oftalma2018134041100-62","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S16355"},{"key":"key-10.17116\/oftalma2018134041100-63","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/131970"},{"key":"key-10.17116\/oftalma2018134041100-64","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0195"},{"key":"key-10.17116\/oftalma2018134041100-65","unstructured":"Pachimkul P, Yuttitham K, Thoophom P. 24-Hour intraocular pressure control between travoprost\/timolol fixed combination, latanoprost\/ timolol fixed combination and standard timolol in primary open angle glaucoma and ocular hypertension. J Med Assoc Thai. 2011;94(suppl 2):81-87."},{"key":"key-10.17116\/oftalma2018134041100-66","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-011-0043-z"},{"key":"key-10.17116\/oftalma2018134041100-67","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0125-9"},{"key":"key-10.17116\/oftalma2018134041100-68","doi-asserted-by":"crossref","unstructured":"Lerner SF, Park KH, Hubatsch DA, Erichev VP, Pachka JA, Roberts TV. Efficacy and tolerability of travoprost 0.004%\/timolol 0.5% fixed-dose combination for the treatment of primary open-angle glaucoma or ocular hypertension inadequately controlled with beta-blocker monotherapy. Natsional'nyi zhurnal glaukoma. 2017;16(3):18-27. (In Russ.)","DOI":"10.1155\/2017\/1917570"},{"key":"key-10.17116\/oftalma2018134041100-69","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0168-y"},{"key":"key-10.17116\/oftalma2018134041100-70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.06.022"},{"key":"key-10.17116\/oftalma2018134041100-71","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0235"},{"key":"key-10.17116\/oftalma2018134041100-72","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S72380"},{"key":"key-10.17116\/oftalma2018134041100-73","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0250-4"},{"key":"key-10.17116\/oftalma2018134041100-74","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902994041"},{"key":"key-10.17116\/oftalma2018134041100-75","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2012.0195"}],"container-title":["Vestnik oftal'mologii"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T22:57:45Z","timestamp":1661900265000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/vestnik-oftalmologii\/2018\/4\/downloads\/ru\/10042465X2018041100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"alternative-id":["oftalma2018134041100"],"URL":"https:\/\/doi.org\/10.17116\/oftalma2018134041100","relation":{},"ISSN":["0042-465X"],"issn-type":[{"value":"0042-465X","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}